documents: FDA-2003-N-0196-0018
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2003-N-0196-0018 | FDA | FDA-2003-N-0196 | Reference 6 - "FDA's Evaluation and Comments on the TEA for Octyl Trlazone." - [Division of OTC Drug Products Memorandum to Dockets Management, July 14, 2003 - "Public Admlnistratlve File for Over-the-Counter Drug Products; Safety and Efficacy, Volume No. 352-01" - Background] | Supporting & Related Material | BKG-Background Material | 2003-07-30T04:00:00Z | 2003 | 7 | 2014-06-09T20:54:14Z | 0 | 0 | 090000648048b59e |
Links from other tables
- 0 rows from regs_document_id in fr_regs_crossref